Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results